Maven Securities’s Boston Scientific BSX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q3
Sell
-2,600
Closed -$279K 496
2025
Q2
$279K Buy
+2,600
New +$263K 0.01% 706
2023
Q4
Sell
-37,100
Closed -$1.96M 946
2023
Q3
$1.96M Buy
37,100
+30,100
+430% +$1.58M 0.02% 405
2023
Q2
$379K Sell
7,000
-400
-5% -$20.9K 0.01% 682
2023
Q1
$370K Sell
7,400
-5,700
-44% -$269K 0.01% 737
2022
Q4
$606K Sell
13,100
-9,600
-42% -$416K 0.01% 540
2022
Q3
$879K Buy
22,700
+6,200
+38% +$249K 0.02% 588
2022
Q2
$615K Sell
16,500
-38,600
-70% -$1.57M 0.02% 517
2022
Q1
$2.44M Buy
55,100
+6,300
+13% +$273K 0.08% 155
2021
Q4
$2.07M Buy
48,800
+10,000
+26% +$420K 0.06% 186
2021
Q3
$1.68M Buy
38,800
+17,700
+84% +$783K 0.05% 292
2021
Q2
$902K Buy
21,100
+2,900
+16% +$122K 0.04% 476
2021
Q1
$703K Buy
+18,200
New +$689K 0.03% 531
2020
Q4
Sell
-6,000
Closed -$229K 594
2020
Q3
$229K Buy
+6,000
New +$231K 0.02% 528

Other funds holding BSX

Maven Securities's BSX Position: Q3 2022 in Review

Maven Securities sold out of Boston Scientific (BSX) in Q3 2022, closing a stake of 12,412 shares — an estimated $498K sold.

Maven Securities first reported a position in BSX in Q2 2020 and held it in 5 quarters. The position peaked at $2.34M in Q4 2020. 864 funds tracked by Wall St. Rank hold BSX as of Q3 2022.

  • Maven Securities reported no remaining Boston Scientific position as of Q3 2022 after selling out during the quarter.
  • Maven Securities sold 12,412 Boston Scientific shares in Q3 2022, an estimated $498K.
  • Maven Securities first reported a position in Boston Scientific in Q2 2020 and held it in 5 quarters.
  • Maven Securities's Boston Scientific position peaked at $2.34M in Q4 2020.
  • 864 funds tracked by Wall St. Rank held Boston Scientific as of Q3 2022.

Based on Maven Securities's 13F filing for Q3 2022, filed 14 Nov 2022.